Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract

Table 3 Correlation between HAI-1 and SNC19/matriptase expression and clinicopathology in gastric cancer tissues [M(QR)]

	Patients	HAI-1	SNC19	HAI-1:SNC19
Age (yr)
<40 yr	3	0.005 (0.011)	0.003 (0.002)	1.415 (1.416)
40-60 yr	17	0.005 (0.016)	0.005 (0.006)	1.680 (2.022)
>60 yr	20	0.005 (0.001)	0.003 (0.003)	0.882 (0.144)
Gender
Men	28	0.005 (0.013)	0.004 (0.004)	1.220 (1.631)
Women	12	0.005 (0.020)	0.003 (0.005)	1.680 (1.571)
Location
Cardia	7	0.005 (0.004)	0.003 (0.002)	1.430 (0.210)
Body	7	0.007 (0.023)	0.004 (0.005)	2.620 (2.846)
Pylorus	17	0.005 (0.015)	0.005 (0.005)	1.080 (1.631)
Unkown	9	0.005 (0.110)	0.003 (0.004)	1.220 (1.219)
Tumor histology
adenocarcinoma	18	0.005 (0.008)	0.004 (0.004)	1.365 (1.442)
Mucoid carcinoma	7	0.005 (0.021)	0.003 (0.008)	1.740 (1.626)
Poorly differentiated carcinoma	11	0.003 (0.016)	0.003 (0.004)	0.882 (2.377)
Unkown	4	0.005 (0.114)	0.005 (0.004)	1.555 (1.386)
N factor
N0	12	0.017 (0.032) a	0.004 (0.005)	2.280 (3.148) e
N1/N2	28	0.004 (0.005)	0.004 (0.005)	1.080 (1.489)
UICC stage
I/II	10	0.017 (0.020) c	0.004 (0.005)	2.280 (2.718) g
III/IV	30	0.004 (0.007)	0.003 (0.004)	1.245 (1.541)
Histological grade
Well	3	0.011 (0.008)	0.003 (0.002）	2.870 (1.753)
Moderately	15	0.005 (0.004)	0.004 (0.004）	1.400 (1.121)
Poorly	22	0.004 (0.017)	0.003 (0.007）	1.150 (0.470)

^aP<0.05,

^cP <0.05 vs lymph node-positive group (N1/N2); ^eP <0.05, ^gP<0.05 vs stage III/IV group.